Evaluation of tumor-associated trypsin inhibitor (TATI) in women with benign and malignant gynecological disease.
Tumor-associated trypsin inhibitor (TATI) was assayed in healthy subjects and in women with benign and malignant gynecological diseases. Significantly lower levels were found in boys than in healthy adult subjects. No variations in level were evident over the course of a 24 h period. At a cut-off level of 20 micrograms/l elevated concentrations were found in 42%, 11.4% and 19% of women with ovarian, endometrial and cervical neoplasia, respectively. In patients with ovarian tumors TATI level were elevated both in mucinous and serous tumors. TATI does not seem to be useful for diagnosis of uterine tumors, but could have a specific place in the study and management of ovarian tumors, in which serum concentrations can reach levels 100-200 micrograms/l. In the other gynecological diseases maximum levels of 30-40 micrograms/l were observed.
Inaudi
P
P
Department of Gynecology and Obstetrics, University of Siena, Italy.
Petrilli
S
S
De Leo
V
V
Bernabei
A
A
Pasqui
L
L
D'Antona
N
N
D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D010051:Ovarian Neoplasms / Q000097:blood* / Q000175:diagnosis; D012016:Reference Values; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000097:blood*; D002577:Uterine Cervical Diseases / Q000097:blood* / Q000175:diagnosis; D014591:Uterine Diseases / Q000097:blood* / Q000175:diagnosis
D014408:Biomarkers, Tumor; D014359:Trypsin Inhibitor, Kazal Pancreatic